ChemoTech kan nu summera stora framsteg efter att ha klarat den tre dagar långa och intensiva revision av Bolagets kvalitetssystem samt granskning av dess kritiska processer som krävs för CE-märkning av medicinteknisk utrustning inom EU.
Read moreErik Penser Bank initierar en analysbevakning av Scandinavian ChemoTech, med bedömningen att aktien har en hög risk, men med en stor potentiell uppsida.
Read moreChemoTechs styrelse har idag beslutat att påbörja en förstudie tillsammans med en grupp ledande specialister inom pankreascancer (cancer i bukspottkörteln) i USA och Europa i syfte att skapa ett internationellt kliniskt samarbete.
Read moreChemoTech can now sum up great progress after completing the three-day long and intensive revision of the Company's quality system and review of its critical processes required for CE marking of medical devices in the EU.
Read moreIn accordance with the newsletter that was published the 5[th] of January 2021, Erik Penser Bank has now begun the implementation of a number of commissioned analyses, the first of which has been published and is available on ChemoTech's website in English: https://www.chemotech.se/investor-relations/financial-analysis/ (https://www.chemotech.se/wp-content/uploads/2021/05/Research-Coverage-Erik-Penser-Bank-ENG.pdf)
Read moreChemoTech's Board of Directors has today decided to begin a feasibility study along with a group of leading specialists in pancreatic cancer in the US and Europe in order to create an international clinical collaboration.
Read more
